Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes

Inclusion Criteria: * Healthy men and women of any ethnic group aged ≥18 years ; * Subjects should have experienced ≥4 recurrences of herpes labialis in the previous 12-months period; * Subjects should have experienced prodromal symptoms in at least 50% of recurrent Herpes labialis (rHL) episodes and should have developed ulcerative lesions that have progressed through vesicle, ulcer, and crust stages in at least 50% of the episodes; * Willingness not to use any topical application (such as cosmetics, lip balm, sunscreens etc…) other than the trial medication in the area of lesion development from start of prodromal symptoms to complete healing; * Willingness not to use any systemic and topical anti-Herpes Simplex Virus (HSV) agent during the trial participation including prescription and over-the-counter (OTC) products; * Willingness not to use any systemic, anti-inflammatory or analgesic agents from start of prodromal symptoms to healing; * Willingness to refrain from mechanical disruption (ie, scrubbing, lancing, shaving) of the prodromal area or lesion after start of treatment with trial medication until end of the trial participation; * Women of child bearing potential and males must use adequate contraception; * Subject must give written informed consent. * Subjects with current lesion may be enrolled, but they must not treat the lesion present at screening/randomization with the trial medication; they should be instructed to wait for their next subsequent lesion Excl…